Sorry super, I’m not really “scaremongering”, I’m actually ramping this thing up...
Good on you Kultz, if it plays out you might be-able to buy back in for 30 cents and almost double your previous position...
"The platform is good, but the p3 trial design sucks. IMHO the trial is a p2b masquerading as a p3.....and that is one of the reasons that US investors will be skeptical. Sure, the is precedent for PFS as a p3 endpoint, but it's the exception rather than the norm. Throw in no US trial sites and its hard to see even a positive result sailing through the FDA."
Funny you mention the trial design, I was talking to a biotech investor from the US and he made similar comments...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable